Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a common heart drug help dialysis patients?

NCT ID NCT07417215

Disease control Sponsor: University Clinical Hospital Mostar Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether the drug sacubitril/valsartan can improve heart function in people with heart failure who are on chronic hemodialysis. 52 patients were split into two groups: one received the drug, the other standard care. Researchers measured changes in heart ultrasound and blood markers over 2 months to see if the drug helps.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
sacubitril/valsartan
What this could lead to
If it works, this could point toward a new treatment option for heart failure in people on dialysis, a group with few effective therapies.
What could go wrong
This is a small, early-phase study with only 52 participants and a short 2-month follow-up. The drug is not yet approved for dialysis patients, and results may not apply to broader populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

52 people

The number who actually took part.

Started

Jan 2026

Finished

May 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: patients on chronic hemodialysis treatment (minimum 1 year); confirmed diagnosis of HFpEF; systolic arterial pressure \>100 mmHg. \- Exclusion Criteria: patients not on chronic hemodialysis treatment; patients with unconfirmed diagnosis of HFpEF; patients with systolic blood pressure \<100 mmHg; patients unwilling to participate in the study; \-

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for End-stage renal disease on hemodialysis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diastolic heart failure end stage renal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heart failure with preserved ejection fraction (hfpef) Hemodialysis Sacubitril/valsartan

Contacts and locations

Locations

  • University Clinical Hospital Mostar

    Mostar, 88000, Bosnia and Herzegovina

More trials for these conditions

Other studies related to the condition(s) this trial covers.